Maze Therapeutics develops precision medicines for common diseases with large unmet medical needs. The company focuses on decoding genetic drivers to create new therapies for serious diseases, particularly kidney disease.

Maze Therapeutics

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders, and biotech industry leaders.

Foresite Capital

Casdin Capital

Alexandria Venture Investments

Google Ventures

ARCH Venture Partners

Third Rock Ventures

Driehaus Capital Management

Woodline Partners

General Catalyst

NS Investment

City Hill Ventures

Matrix Capital Management

Moore Strategic Ventures

Terra Magnum Capital Partners (""""TMCP"""")""

"There are always people who will give you reasons why you can’t do something…They’ll say it's too hard or it can’t be done. But that’s exactly why we should be working on it.” 

This is one of many inspiring quotes expressed by our Chairman and Co-founder Charles Homcy during his recent visit to our office. In celebration of our 5-year milestone as a company, Charles shared his background, career journey and what led him to Maze. We're thankful for his time and insights.

We're celebrating #NationalInternDay! Thank you to our interns for bringing curiosity, enthusiasm and great ideas to Maze. Your contributions have made a difference to our team, and we are excited to continue to watch you grow in your careers.

Please join us in welcoming Courtney Phillips to Maze as our General Counsel. Courtney is a seasoned legal and business executive with deep biopharmaceutical experience. We are excited to add her expertise to the Maze team and look forward to accomplishing big things together as we seek to leverage the power of human genetics to bring new precision medicines to patients with common diseases.

This year is a significant one for us as we commemorate five years of Maze. In a short period of time, we're proud of the progress we've made within the common and rare disease communities with the help of our team members and valued partners. Our mission to translate #geneticinsights into groundbreaking therapies has never been stronger as we expand our clinical portfolio.

As we celebrate this milestone, hear from our CEO Jason Coloma, Ph.D., Chairman of the Board and Third Rock Ventures partner Charles Homcy, M.D., and Board Member Sekar (Sek) Kathiresan, M.D., as they speak to our progress to date and vision for the future ahead.

In honor of #PrideMonth, Mazers came together for a happy hour in support of the LGBTQ+ community. At Maze, we believe that the best innovations come from a team that embraces diverse perspectives and experiences, and we're proud to have that culture and an environment where freedom of expression is welcomed and encouraged. Thank you to all Mazers for your yearlong support toward this aim.

The National Kidney Foundation's Northern California Kidney Walk is one of our favorite events of the year! Not only do we get to come together as Team AMAZEing and make memories as an organization, but by participating in this walk, we are contributing directly to the #kidneydisease community. We are proud to have surpassed our fundraising goal this year to (1) ensure those living with chronic kidney disease get diagnosed, treated and supported early, (2) provide tools to help promote #kidneyhealth, and (3) help support life-saving research. Thanks to all Mazers for your participation and contributions.

Our offices are closed today to commemorate #Juneteenth, a significant day which marks the end of slavery in the United States and the continued fight for equity and justice. We honor this pivotal moment in our nation's history and are reflecting on how we, both as individuals and as an organization, can take part in advancing a more just and inclusive future for all.

We are proud to announce that we have completed an exclusive worldwide license agreement with Shionogi & Co., Ltd for the rights to MZE001. MZE001 is a small molecule inhibitor of GYS1, an enzyme involved in glycogen synthesis, that is designed to reduce glycogen concentration in muscles. The results from the Phase 1 study of MZE001 suggest that it has the potential to be the first oral therapy for the treatment of #Pompedisease, a congenital metabolic #raredisease. Shionogi has an impressive track record of developing and delivering innovative treatments for patients, and we are confident in their commitment to the advancement of this asset. Read the full announcement here: https://lnkd.in/euv979a8

Today marks the very first annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day. APOL1-mediated kidney disease is a genetic condition that can cause kidney failure, and disproportionately affects people of Western and Central African descent. We're raising awareness alongside the American Kidney Fund for those living with APOL-1 #kidneydisease. At Maze, we're developing MZE829, a potential oral medicine that is currently in Phase 1 clinical trials. We invite you to learn more and raise awareness about AMKD and promote being #APOL1aware. By working together as a community, we can expand our understanding of APOL1's association with kidney disease. Join us in making a difference here: https://lnkd.in/eBbath4Z

We recently hosted a Botanicals and Brews celebration in honor of #EarthDay2024. Thanks to Mazers Terrence Satterfield and Vinita Shah B. for leading an engaging workshop which included growing plants without soil, better known as hydroponic gardens, a hobby that blends science with #sustainability to promote environmentally friendly food production. We enjoyed celebrating our planet while making memories together!

news impact assignment basic	general
public peers	general	Sep 3, 2024 11:51 PM	408f82d5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 11:54 PM	84a03ce4
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Sep 3, 2024 11:51 PM	be37697c
translate crunchbase fundingrounds	general
peers	general	Sep 3, 2024 11:51 PM	e0e6e305
news basic	general	Sep 3, 2024 11:51 PM	9e338a05
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

MAZE

COM:MAZETX

Maze Therapeutics